Breast cancer patients who participated in a remote weight loss intervention program lost an average of 4.7% of their baseline body weight after one year, while those in the education only control group gained an average 1% of their baseline weight, according to a new report from Dana-Farber Cancer Institute investigators. The findings from the Breast Cancer Weight Loss (BWEL) clinical trial set the stage for ongoing research to determine if weight loss following breast cancer treatment can reduce the risk of cancer recurrence and extend survival.
This article was originally published on MedicalXpress.com
